Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 134M | 117M | 91M | 58M | 55M |
| Gross Profit | 84M | 68M | 55M | 32M | 32M |
| Operating Income | 7M | -12M | -10M | -7M | -4M |
| EBITDA | 16M | -8M | 5M | -5M | -3M |
| Net Income | 5M | -16M | 660K | -8M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.44
+0.00% today
1Y Change
-23.88%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xtant Medical Holdings, Inc. (XTNT) is a Healthcare stock with a market cap of $80.00M and listed on AMEX. The stock last traded around $0.44 and down 23.9% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +14.2%, EPS growth of +133.3%, a dividend yield of 0.0%. What stands out right now is revenue +14.2%, EPS +133.3%, free cash flow +163.5% with operating margin 5.4% and ROIC 6.5%. Valuation is more restrained than many high-expectation growth names at P/E 15.7 and price/sales 0.6. Stock Foundry combines XTNT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XTNT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XTNT Max Drawdown
-53.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XTNT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$55.3M
-4.7% YoY
FY Net Income
-$4.8M
+42.9% YoY
Free Cash Flow
-$1.7M
+76.4% YoY
Revenue Growth
+14.2%
EPS Growth
+133.3%
Gross Margin
62.9%
Net Margin
3.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 134M | 117M | 91M | 58M | 55M |
| Gross Profit | 84M | 68M | 55M | 32M | 32M |
| Operating Income | 7M | -12M | -10M | -7M | -4M |
| EBITDA | 16M | -8M | 5M | -5M | -3M |
| Net Income | 5M | -16M | 660K | -8M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 6M | 6M | 20M | 18M |
| Total Assets | 94M | 94M | 93M | 60M | 55M |
| Total Liabilities | 43M | 51M | 41M | 26M | 24M |
| Shareholder Equity | 51M | 43M | 51M | 34M | 31M |
| Total Debt | 29M | 35M | 24M | 17M | 17M |
| Net Debt | 12M | 29M | 18M | -3M | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
439K
+108.2% YoY
Capital Expenditures
2M
-19.9% YoY
Free Cash Flow
2M
+76.4% YoY
Key ratios
Gross Margin
62.9%
Operating Margin
5.4%
Net Margin
3.7%
ROE
10.3%
Debt / Equity
0.56x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.